

	AASLD	EASL	APASL	DDW	KASL
2013	2	0	3	1	N/A
2014	1	2	2	1	N/A
2015	1	1	5	0	2
2016	1	1	1	0	3
2017	NA	1	3	0	2

Abbreviations: AASLD; American Association for the Study of Liver Diseases, EASL; European Association for the Study of the Liver, APASL; Asian Pacific Association for the Study of the Liver, DDW; Digestive Disease Week, KASL; Korean Association for the Study of the Liver

1 **Supplemental table 1. Major article searching**

2

3

4

5

6

7

8

Data base	Search Strategy	Items
Medline	1. (chronic hepatitis B) OR (chronic hepatitis B [tw])	19336
	2. (tenofovir) OR (tenofovir [tw])	5750
	3. (entecavir) OR (entecavir [tw])	2129
	4. 2 OR 3	7165
	5. 1 AND 4	1997
EMBASE	1. ('chronic hepatitis b'/exp OR 'chronic hepatitis b':ab,ti OR 'chronic hepatitis b'/de) AND [embase]/lim	22852
	2. ('tenofovir'/exp OR 'tenofovir':ab,ti OR 'tenofovir'/de) AND [embase]/lim	17559
	3. ('entecavir'/exp OR 'entecavir':ab,ti OR 'entecavir'/de) AND [embase]/lim	6930
	4. 2 OR 3	21691
	5. 1 AND 4	4874
Cochrane	1. chronic hepatitis B:ti,ab,kw	4412
	2. tenofovir:ti,ab,kw	1827
	3. entecavir:ti,ab,kw	494
	4. 2 OR 3	2207
	5. 1 AND 4	679

9 **Supplemental table 2. Search strategies**

10

Study	Journal	Reason for exclusion
Asselah (2013)	Clin Liver Dis 17(3): 445-450.	Review
Batirel (2014)	Int J Infect Dis 28: 153-159.	No adequate data of renal function
Bircan (2017)	Clin Res Hepatol Gastroenterol. 2017 Jul 27. pii: S2210-7401(17)30152-3	No adequate data of renal function
Bradshaw (2014)	Aliment Pharmacol Ther 39(9): 992.	No adequate data of renal function, Commentary
Bunchorntavakul (2016)	J Med Assoc Thai 99 Suppl 2: S1-8.	No adequate data of renal function
Buti (2009)	J Hepatol 51(4): 640-646.	No adequate data of renal function
Ceylan (2013)	Eur Rev Med Pharmacol Sci 17(18): 2467-2473.	No adequate data of renal function
Chen (2010)	Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 24(5): 364-366.	No TDF arm
Chen (2013)	BMC Res Notes 6: 349.	No TDF arm
Chen (2014)	Aliment Pharmacol Ther 40(4): 406-407.	No adequate data of renal function, Letter
Cho (2015)	PLoS One 10(6): e0130392.	No adequate data of renal function
Cholongitas (2015)	Ann Gastroenterol. 2015 Jan-Mar;28(1):109-117.	No adequate data of renal function, Not extractable (Box Plot)
Deng (2013)	Zhong Nan Da Xue Xue Bao Yi Xue Ban 38(12): 1193-1207.	No adequate data of renal function, Meta analysis
Dienstag (2007)	Clin Drug Investig 27(1): 35-49.	No TDF arm
Dogan (2012)	Turk J Gastroenterol 23(3): 247-252.	No adequate data of renal function
Fong (2015)	Dig Dis Sci 60(11): 3465-3472.	No adequate data of renal function
Fung (2014)	J Gastroenterol Hepatol 29(3): 428-434.	Review
Gao (2014)	Aliment Pharmacol Ther 39(6): 629-637.	No adequate data of renal function
Gish (2012)	Clin Gastroenterol Hepatol 10(8): 941-946; quiz e968.	No adequate data of renal function
Gluhovschi (2011)	Immunopharmacol Immunotoxicol 33(4): 744-750.	No TDF arm

Goyal (2015)	Indian J Gastroenterol 34(4): 286-291.	No adequate data of renal function
Guzelbulut (2012)	Hepatogastroenterology 59(114): 477-480.	No adequate data of renal function
Ha (2016)	J Clin Gastroenterol. 2016 Feb;50(2):169-74	No adequate data of renal function
Huang (2015)	Int J Clin Exp Med 2015;8(1):666-673	No adequate data of renal function
Hung(2015)	Antimicrob Agents Chemother. 2015;59(6):3168-73.	No adequate data of renal function, Not extractable (Acute Exacerbation)
Jayakumar (2012)	J Lab Physicians. 2012 Jan;4(1):10-6	No adequate data of renal function
Jia (2016)	Chin J Hepatol, 2016,24(09): 643-646	No adequate data of renal function, Not same interval of repeating measure with other studies
Kim (2013)	Clin Mol Hepatol 19(4): 409-416.	No TDF arm
Kiyici (2015)	Hepatogastroenterology 62(140): 982-6.	No adequate data of renal function (No SD)
Koike (2017)	Hepatol Res. 2017 Apr 3. doi: 10.1111/hepr.12902	No adequate data of renal function
Koklu (2013)	Clin Gastroenterol Hepatol. 11(1):88-94.	No adequate data of renal function
Kwon (2015)	Niger J Clin Pract 18(6): 796-801.	No adequate data of renal function
Li (2011)	Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 25(4): 295-297.	No TDF arm
Liang (2011)	Zhonghua Gan Zang Bing Za Zhi 19(7): 516-520.	No TDF arm, Experimental study, one patient
Liaw (2011)	Hepatology 53(1): 62-72.	No adequate data of renal function
Lu (2015)	J Viral Hepat 22(8): 675-681.	Not monotherapy
Maggi (2015)	J Antimicrob Chemother 70(4): 1150-1154.	No ETV arm
Mallet (2015)	Clin Gastroenterol Hepatol. 13(6): 1181-1188 e1181.	No adequate data of renal function
Maratea (2013)	Aliment Pharmacol Ther 37(5): 584-585.	No adequate data of renal function, Letter
Marcellin (2014)	Antivir Ther 19(3): 235-243.	No adequate data of renal function

Marlone (2017)	Braz J Infect Dis. 2017 Jul - Aug;21(4):441-447	No adequate data of renal function
Mauss (2011)	J Hepatol. 2011 Dec;55(6):1235-40	No adequate data of renal function, Mean eGFR variation/per year
Miquel (2013)	Ann Hepatol 12(2): 205-212.	No adequate data of renal function
Ozaras (2014)	Eur J Gastroenterol Hepatol 26(7): 774-780.	No adequate data of renal function
Ozeki (2013)	Nihon Shokakibyō Gakkai Zasshi 110(1): 44-55.	No TDF arm
Pan (2013)	Antivir Ther 18(7): 841-852.	Review
Papatheodoridis (2015)	J Hepatol. 2015 Feb;62(2):363-70.	No adequate data of renal function
Papatheodoridis (2017)	Hepatology. 2017 Nov;66(5):1444-1453	No adequate data of renal function
Park (2013)	Clin Mol Hepatol 19(1): 29-35.	No TDF arm
Park (2014)	J Gastroenterol Hepatol 29(5): 1005-1011.	No TDF arm
Park (2017)	BMC Gastroenterol. 2017 Mar 9;17(1):39	No adequate data of renal function
Pol (2012)	J Viral Hepat 19(6): 377-386.	Review
Qi (2015)	Medicine (Baltimore) 94(15): e646.	No TDF arm, Not monotherapy
Qi (2015)	J Viral Hepat 22(1): 46-54.	No TDF arm
Rago (2010)	Antivir Ther 15(6): 929-932.	Case report
Ridruejo (2012)	Expert Opin Drug Saf 11(3): 357-360.	Review
Ridruejo (2014)	World J Gastroenterol 20(23): 7169-7180.	Review
Riveiro-Barciela (2017)	Dig Dis Sci. 2017 Mar;62(3):784-793.	Not monotherapy
Rodriguez-Novoa (2016)	J Clin Gastroenterol. 2016;50(9):779-789.	No adequate data of renal function (Median +/- SD)
Sadler (2014)	Aliment Pharmacol Ther 39(11): 1339.	No adequate data of renal function
Saeedi (2017)	Ann Hepatol. 2017 March-April;16(2):207-214	No adequate data of renal function

Shi (2016)	Biomed Res Int. 2016;2016:6725073	No adequate data of renal function
Shin (2016)	Medicine (Baltimore) 95(1): e2400.	No adequate data of renal function
Sollima (2015)	Clinical Management Issues, 9(2), 45-55	No adequate data of renal function
Sriprayoon (2017)	Hepatol Res. 2017;47(3):E161-E168.	No adequate data of renal function (No SD)
Srivastava (2016)	Indian J Med Res. 2016 Sep; 144(3): 424-432	No adequate data of renal function
Tarsetti (2015)	Clinical Management Issues. 9(4), 95-100.	No adequate data of renal function
Thu (2015)	BMC Pharmacol Toxicol 16: 38.	No adequate data of renal function, (Nucleoside vs Nucleotide)
Tien (2015)	Dig Dis Sci 60(2): 566-572.	No adequate data of renal function
Tsai (2016)	Clin Microbiol Infect. 2016 Jan;22(1):95.e1-95.e	No adequate data of renal function (No SD)
Tsai (2017)	J Formos Med Assoc. 2017 Jul;116(7):512-521	No adequate data of renal function (No SD)
Wu (2017)	Clin Microbiol Infect. 2017 Jul;23(7):464-469	No adequate data of renal function (No SD)
Yegin (2014)	Hepatobiliary Pancreat Dis Int 13(6): 602-611.	No adequate data of renal function
Yu (2014)	Saudi J Gastroenterol 20(6): 350-355.	No TDF arm
Zhang (2015)	J Med Virol 87(6): 1013-1021.	No ETV arm
Zhang (2017)	Int J Clin Exp Med 2017;10(8):12329-12335	No adequate data of renal function
Zoulim (2015)	J Hepatol 62(1): 56-63.	Not monotherapy

Supplemental table 3. List of citations excluded, including justification

11

12

13

14

MDRD-4	$186 \times S_{cr}^{-1.154} \times \text{age}^{-0.203} \times 1.212 \text{ (if black)} \times 0.742 \text{ (if female)}$
Re-expressed after IDMS calibration	$175 \times S_{cr}^{-1.154} \times \text{age}^{-0.203} \times 1.212 \text{ (if black)} \times 0.742 \text{ (if female)}$
MDRD-6	$170 \times S_{cr}^{-0.999} \times \text{age}^{-0.176} \times \text{BUN}^{-0.170} \times \text{albumin}^{+0.318} \times 1.180 \text{ (if black)} \times 0.762$ (if female)
Re-expressed after IDMS calibration	$161.5 \times S_{cr}^{-0.999} \times \text{age}^{-0.176} \times \text{BUN}^{-0.170} \times \text{albumin}^{+0.318} \times 1.180 \text{ (if black)} \times$ $0.762 \text{ (if female)}$
MDRD-7	$170 \times sCr^{-0.999} \times \text{age}^{-0.176} \times 0.762 \text{ [if woman]} \times 1.180 \text{ [if the patient is}$ African-American] $\times \text{BUN}^{-0.170} \times \text{serum albumin}^{+0.318}$ (sCr is expressed in mg/dL, age in years, BUN in mg/dL, serum albumin in g/dL); $eGFR(\text{ml}/\text{min}/1.73\text{m}^2) = 141 * \min(\text{Scr}/\kappa, 1)^\alpha * \max(\text{Scr}/\kappa, 1) -$ $1.209 * 0.993 \text{Age} * 1.018 \text{ if female, } * 1.212 \text{ if Black}$ $\kappa = 0.7 \text{ for females and } 0.9 \text{ for males}$ $\alpha = -0.329 \text{ for females, } -0.411 \text{ for males}$ min : minimum of Scr/ κ or 1 max : maximum of Scr/ κ or 1
CKD-EPI (IDMS traceable)	

Abbreviations: MDRD, modification of diet in renal disease; IDMS, isotope dilution mass spectrometry; CKD-EPI, chronic kidney disease epidemiology collaboration; Scr, serum creatinine; BUN, blood urea nitrogen

15 **Supplemental table 4. Formulas to evaluate renal function**

	Group 1	Group 2	Equation
Sample size	N_1	N_2	$N_1 + N_2$
Combine Mean	M_1	M_2	$\frac{N_1M_1 + N_2M_2}{N_1 + N_2}$
Subtract Mean	M_1	M_2	$M_2 - M_1$
Combine SD	SD_1	SD_2	$\sqrt{\frac{(N_1 - 1)SD_1^2 + (N_2 - 1)SD_2^2 + \frac{N_1N_2}{N_1 + N_2}(M_1^2 + M_2^2 - 2M_1M_2)}{N_1 + N_2 - 1}}$
Subtract SD	SD_1	SD_2	$\sqrt{SD_1^2 + SD_2^2 - 2SD_1SD_2 * 0.7}$

16 **Supplemental table 5. Equations for modifying data**

17

18

19

20

21

Bias	Ha	Park	Lopez	Idilman	Koklu	Tsai	Yu	Koksal	Lee
Selection									
1) Representativeness of the exposed cohort	★	★	★	★	★	★	★		★
2) Selection of the non exposed cohort	★	★	★	★	★	★	★		★
3) Ascertainment of exposure	★	★	★	★	★	★	★	★	★
4) Demonstration that outcome of interest was not present at start of study	★	★			★			★	
Comparability									
1) Comparability of cohorts on the basis of the design or analysis	★	★	★			★	★	★	
Outcome									
1) Assessment of outcome	★	★	★	★	★	★	★	★	★
2) Was follow-up long enough for outcomes to occur	★	★	★	★	★	★	★	★	★
3) Adequacy of follow up of cohort	★	★	★	★	★	★		★	

22 **Supplemental table 6. Newcastle-Ottawa scale for non-randomized studies**

23

24

25

Certainty assessment							No of patients		Effect	Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	TDF	ETV	Absolute (95% CI)		
Creatinine - 6months											
5	observational studies	serious	not serious	not serious	not serious	· dose response gradient	833	891	MD 0.03 higher (0.02 higher to 0.04 higher)	⊕⊕○○ Low	CRITICAL
Creatinine - 12 months											
9	observational studies	serious	not serious	not serious	not serious	· all plausible residual confounding would reduce the demonstrated effect · dose response gradient	992	1174	MD 0.05 higher (0.02 higher to 0.08 higher)	⊕⊕⊕○ Moderate	CRITICAL
Creatinine - 24 months											
6	observational studies	serious	not serious	not serious	not serious	· publication bias strongly suspected · all plausible residual confounding would reduce the demonstrated effect · dose response gradient	658	766	MD 0.07 higher (0.01 higher to 0.13 higher)	⊕⊕○○ Low	CRITICAL

26 Supplemental table 7. Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria to appraise quality of
27 evidence

Author Year Country	Inclusion Criteria	Exclusion Criteria	Renal Parameter
Ha, 2015 ^[14] USA	naïve CHB eGFR > 50 ml/min/1.73m ² , HTN, DM	Co-infection, eGFR < 50 ml/min/1.73m ²	Creatinine CCG, MDRD
Koklu, 2015 ^[24] Turkey	naïve CHB HTN, DM, eGFR < 60 ml/min/1.73m ²	Co-infection, HCC, Malignancy, Orgran transplantation, Acute liver failure	Creatinine MDRD
Lopez, 2016 ^[22] Spain	HTN, DM, eGFR < 60 ml/min/1.73m ² Concomitant drugs†	Co-infection‡	Creatinine CKD-EPI
Idilman, 2015 ^[25] Turkey	naïve CHB HCC (n=17/355)	Co-infection‡	Creatinine
Park, 2017 ^[20] Korea	HbsAg > 6month, DM, HTN Concomitant drugs†	HCC / Death in 24month Massive bleeding eGFR < 60 ml/min/1.73m ²	Creatinine CKD-EPI
Tsai, 2016 ^[21] Taiwan	All Impaired renal function : eGFR 30-90 ml/min/1.73m ² HCC (n = 13/99)	DM,HTN, Chemotherapy, Orgran transplantation, Co- infection	Creatinine CCG, MDRD, CKD-EPI
Yu, 2015 ^[16] Korea	naïve CHB HTN, DM, HCC (n = 12/107)	Other Malignancy, CTx, RTx, Orgran transplantation, Co-infection‡	Creatinine MDRD
Koksal, 2016 ^[23] Turkey	naïve CHB	DM, HTN, Malignancy Thyroid/Renal disease	Creatinine, UACR, Cystatin C CKD-EPI-Cys, CKD-EPI-Cr-Cys
Lee, 2015* ^[15]	naïve CHB	Hepatorenal syndrome	Creatinine

Korea			
-------	--	--	--

28 Abbreviations: CHB, chronic hepatitis B; eGFR, estimated glomerular filtration rate; HTN, hypertension; DM, diabetes mellitus; HCC, hepatocellular carcinoma; MDRD, modification of diet in renal disease; CKD-
29 EPI, chronic kidney disease epidemiology collaboration; Cr, creatinine; Cys, Cystatin-C; UACR, urinary albumin-to-creatinine ratio; CTx, Chemotherapy; RTx, radiotherapy; RMSRC, reclassified to a more severe
30 renal classification; * : Abstract, † : Concomitant drugs : NSAID, Diuretics, Statin, ACEi, Cardiovascular drugs(Isosorbide, b-blocker, anticoagulants), TMP-SMX, OHA, immunosuppressant, ‡ : Co-infection : HCV,
31 HDV, HEV

32 **Supplemental table 8. Inclusion and exclusion criteria and parameters used in article to indicate renal function.**

33